Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

Also called NCT07898709

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Al-Azhar University (from the registry)
Registry
  • NCT NCT07898709
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07898709. Randomized; no masking; primary purpose treatment. Start 2027-01 (anticipated); primary completion 2027-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
Condition
No Reflow Phenomenon
Condition
Reperfusion Injuries, Myocardial
Condition
STEMI - ST Elevation Myocardial Infarction
Condition
Sodium Glucose Co-Transporter 2 Inhibitors
Condition
Empagliflozin
Condition
Dapagliflozin
Intervention (Drug)
Empagliflozin (SGLT2i)
Intervention (Drug)
dapagliflozin
Intervention (Drug)
Standard medical treatment
Lead sponsor
Al-Azhar University (class: other)

Record details

Record id
cardio:ct-nct07898709
Content hash
f04ac6902189463b921a94f1f78ef5b8cfdc75ee1fb7578825090d3c781e8422